Compare AstraZeneca plc (AZN) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Kinder Morgan Inc — how do they compare? AstraZeneca plc trades at $167.14 (market cap $253.13B), while Kinder Morgan Inc trades at $32.5 (market cap $72.40B). The key difference: AstraZeneca plc is far larger — about 3.5× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.61%). Which is the better fit depends on your goals.
| AZN | KMI | |
|---|---|---|
Market Cap | $253.13B | $72.40B |
Sector | Health | Energy |
52-Week High | $209.48 | $34.31 |
52-Week Low | $137.44 | $25.84 |
Enterprise Value | $279.37B | $104.27B |
Dividend Yield | 1.92% | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
KMI trades at $32.24, up 0.37% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and revenue growth is projected to reach $17.5B in 2026. Analyst sentiment is mixed but leans positive, with 47% recommending a buy, supported by a stable dividend and a $10.1B project backlog focused on natural gas infrastructure.
The outlook for KMI is favorable, driven by rising LNG demand and contracted cash flows, though risks include commodity price volatility and high debt levels. The stock offers a solid dividend yield and growth potential from infrastructure investments, making it attractive for income and growth investors despite macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
